EAST LONG MEADOW, Mass., March 21 /PRNewswire/ -- The biolitec Group of Jena, Germany, announces the appointment of Carl F. Siekmann to the newly created position of Vice President, Corporate Development for biolitec Pharma Ltd. Initially based out of biolitec’s U.S. laser and fiber optic corporate facility in East Longmeadow, MA, Mr. Siekmann will direct the Company’s corporate and business development efforts to establish the platform for a U.S. Pharma operating presence. In this capacity, he will report directly to Dr. Wolfgang Neuberger, President and CEO of the biolitec Group.
“The addition of Carl to the biolitec management team brings proven success in deal-making, business development, fundraising and general management,” said Dr. Neuberger. “We are confident that he will provide the necessary leadership in partnering and commercializing our pharmaceutical portfolio, and in ultimately attaining a leading position for biolitec in photodynamic therapeutic products.”
Most recently, Mr. Siekmann was Vice President of Corporate Development Services at The Mattson Jack Group where he advised a worldwide client base on corporate development and commercialization strategies. Prior to Mattson Jack, he held various senior management positions within the pharmaceutical industry including Executive Vice President, Corporate Development for Sheffield Pharmaceuticals and Vice President, Business Development for Bock Pharmacal Company.
Mr. Siekmann’s previous experience includes progressive management responsibilities in sales, marketing, business development and general management for Marion Laboratories, Bristol-Myers Squibb, Abbott Laboratories and Erbamont N.V.
ABOUT BIOLITEC
The biolitec Group, headquartered in Jena, Germany, is a biopharmaceutical company involved in the development and production of photosensitiser drugs for use in Photodynamic Therapy (PDT) and is a leading developer and manufacturer of diode lasers, optical fibers and accessories for application in a wide range of medical specialties. The biolitec Group includes the CeramOptec(R) brand of diode lasers and medical and industrial fibers and biolitec Pharma, the manufacturer of Foscan(R). The biolitec Group is unique in providing all core competencies for PDT -- lasers, fibers and photosensitisers. The company is listed on Frankfurt’s Neuer Markt (symbol: BIB) and has offices in eight countries including subsidiary manufacturing and sales sites in Bonn, USA, Scotland, France, Malaysia and Latvia.
Biolitec Pharma, Ltd. is focused on integrating a growing pharmaceutical pipeline with the advanced biolitec photo technology platform to provide targeted PDT therapeutic solutions to treat unmet medical needs in the areas of cancer, cardiovascular disease, auto-immune disease, infectious disease and dermatology. The company’s lead PDT product, Foscan(R) (temoporfin), has been approved by the European Agency for the Evaluation of Medicinal Products (EMEA) for palliative treatment of head and neck cancer.
biolitec Group
CONTACT: Kelly Laban of Kovak-Likly Communications, +1-203-762-8833 ext.15, or KLaban@KLCpr.com, for biolitec Group
